Center-Authored Papers

Filters: Author is Baden, Lindsey R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL et al..  2010.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.. Blood. 116(24):5111-8. Abstract
Williams WB, Liao H-X, Moody AM, Kepler TB, Alam MS, Gao F, Wiehe K, Trama AM, Jones K, Zhang R et al..  2015.  Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.. Science (New York, N.Y.). Abstract
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ et al..  2015.  Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083).. The Journal of infectious diseases. Abstract
P
Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S et al..  2012.  Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transpl. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(26):3194-201. Abstract
K
Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M et al..  2012.  Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults.. PloS one. 7(1):e29231. Abstract
Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I et al..  2013.  Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery.. The Journal of infectious diseases. 208(5):818-29. Abstract
H
Hammond SP, Swaminathan S, Bensinger WI, Baden LR.  2014.  Hepatitis B virus screening and potential reactivation in patients undergoing treatment for cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(12):1655-7.
G
Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, De Rosa SC, Kalams SA, McElrath MJ et al..  2014.  Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles.. The Journal of infectious diseases. Abstract
F
Fuchs JD, Bart P-A, Frahm N, Morgan C, Gilbert PB, Kochar N, De Rosa SC, Tomaras GD, Wagner TM, Baden LR et al..  2015.  Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.. Journal of AIDS & clinical research. 6(5) Abstract
C
Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR.  2010.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.. JAMA : the journal of the American Medical Association. 304(3):275-83. Abstract
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker L-G, McElrath MJ et al..  2011.  A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204).. PloS one. 6(8):e21225. Abstract
Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, Suscovich TJ, Frahm N, Linde C, Mahan AE et al..  2015.  Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.. Cell. 163(4):988-98. Abstract
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
B
Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody AM, Frahm N, Montefiori DC, Hay CM, Goepfert PA et al..  2017.  Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.. PloS one. 12(7):e0179597. Abstract
Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P et al..  2011.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.. Vaccine. 29(32):5203-9. Abstract
Barouch DH, Liu J, Peter L, Abbink P, Iampietro JM, Cheung A, Alter G, Chung A, Dugast A-S, Frahm N et al..  2013.  Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001).. The Journal of infectious diseases. 207(2):248-56. Abstract
Baden LR, Karita E, Mutua G, Bekker L-G, Gray G, Page-Shipp L, Walsh SR, Nyombayire J, Anzala O, Roux S et al..  2016.  Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.. Annals of internal medicine. Abstract
Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N et al..  2011.  Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects.. The Journal of infectious diseases. 204(10):1541-1549. Abstract